Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 July 2018Website:
http://www.liquidia.comNext earnings report:
13 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 22:16:16 GMTDividend
Analysts recommendations
Institutional Ownership
LQDA Latest News
Liquidia's Yutrepia, a competitor to United Therapeutics' Tyvaso, faces potential market entry in 2025, with promising clinical data and a competitive therapeutic profile. Despite financial challenges and intense competition, Liquidia's low valuation and upcoming product launches present a compelling investment opportunity. Liquidia's legal battles with United Therapeutics are nearing resolution, potentially clearing the path for Yutrepia's commercial launch by mid-2025.
Liquidia Corporation (NASDAQ:LQDA ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Rusty Schundler - General Counsel Rajeev Saggar - Chief Medical Officer Michael Kaseta - Chief Operating Officer & Chief Financial Officer Scott Moomaw - Chief Commercial Officer Conference Call Participants Julian Harrison - BTIG Jason Gerberry - Bank of America Greg Harrison - Scotiabank Kambiz Yazdi - Jefferies Cory Jubinville - LifeSci Capital Matt Kaplan - Ladenburg Thalmann Ryan Deschner - Raymond James Operator Good morning and welcome everyone to Liquidia Corporation Third Quarter 2024 Financial Results and Corporate Update Conference Call. My name is Michelle [ph] and I will be your conference operator today.
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.37 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share a year ago.
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
What type of business is Liquidia?
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
What sector is Liquidia in?
Liquidia is in the Healthcare sector
What industry is Liquidia in?
Liquidia is in the Biotechnology industry
What country is Liquidia from?
Liquidia is headquartered in United States
When did Liquidia go public?
Liquidia initial public offering (IPO) was on 26 July 2018
What is Liquidia website?
https://www.liquidia.com
Is Liquidia in the S&P 500?
No, Liquidia is not included in the S&P 500 index
Is Liquidia in the NASDAQ 100?
No, Liquidia is not included in the NASDAQ 100 index
Is Liquidia in the Dow Jones?
No, Liquidia is not included in the Dow Jones index
When was Liquidia the previous earnings report?
No data
When does Liquidia earnings report?
The next expected earnings date for Liquidia is 13 March 2025